Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Tonix Pharmaceuticals Soars on Monkeypox Vaccine Patent, TNX-801 Could be an 'Effective and Better Tolerated' Vaccine According to Analyst

Published 2022-06-01, 10:28 a/m
TNXP
-

By Vlad Schepkov

Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) are keeping traders busy early into Wednesday’s trading session, soaring close to 50% in heavy trading, on the news that the company has received a US patent for TNX-801 – its smallpox and monkeypox vaccine and recombinant pox virus platform technology.

The announcement times well into the increased attention the World Health Organization (WHO), the media, and the investors are paying to the growing number of monkeypox cases reported around the globe - according to the latest WHO figures, as of May 31st, 2022, there were over 550 confirmed cases in 30 countries.

Smallpox, although considered an eradicated disease, routine vaccinations against which have been mostly discontinued in the 1970s, has long been identified as a potential biological weapon – the virus was confirmed to have been studied by Soviet and later Russian biolabs.

The traditional pox vaccine - Jynneos, from Bavarian Nordic – although renowned for efficacy and being instrumental to the original disease eradication, is also known for its safety and tolerability concerns including pain, swelling and severe allergic reactions.

While Jynneos is based on vaccinia, a virus related to smallpox, Tonix’s new TNX-801 technology uses genetic sequencing analysis of smallpox, cowpox, and horsepox to construct a synthetic-chimeric horsepox virus. Pre-clinical data and animal studies have shown the candidate to offer strong protection, while inducing fewer side effects. Noble Capital Markets recently noted that “TNX-801 is in development to be an effective and better tolerated smallpox vaccine.”

TNXP, which hit an all-time low of $1.91 just 2 weeks back, has since nearly doubled and is trading around $3.60 per share.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.